The usual and professionally accepted course to gain attention and interest in the potential of a new therapy is to either have a full publication on the findings submitted to a peer reviewed journal or presentation of the findings at a well attended and widely known scientific/medical society's annual meeting or special conference. Much publicity can be garnered from these appropriate routes. As just one example, there is immense scientific, investment and general news organizations' reporting personnel that eagerly await and attend the annual American Society for Cinical Oncology (ASCO) meeting held each year the first week of June. Much full coverage is garnered from that meeting.
I pointed out recently on this posting site the availability of what I believe is the "white paper" on LDN therapy. I gave the link to the Pubmed website to view the abstract. Here it is again: www.ncbi.nlm.nih.gov/pubmed/29885638. Since there is cost ($37.95) to obtain the full article fro the journal publisher, not sure who has a full copy.
Please note the authors on the publication-it IS an IMUN article. There is only minimal discussion in the entire article contained in a very short paragraph titled LDN and AIDS. Only two references are indicated, one to a 23 year old article by the late Bernard Bihari, M.D. and a reference to a Fengping Shan group article covering effects of LDN on macrophage function that contains only a notation that "In Nigeria, LDN has been approved for the treatment of AIDS." There is absolutely no reference to the actual results of the bridging study of LDN in Nigeria completed well over two years ago.
Why?-easy answer-nothing was published or presented at a conference covering this, and I quote you, "huge" piece of knowledge. If you want to pursue the PR failings of IMUN you should be pressing to know why no presentation or publication on the results.
